Antiplatelet Therapy in Cardiovascular Disease

Antiplatelet Therapy in Cardiovascular Disease

By: Ron Waksman (editor), Paul A Gurbel (editor), Michael A. Gaglia (editor)Hardback

Up to 2 WeeksUsually despatched within 2 weeks


Edited by a team of the world s leading interventional cardiologists and educators, this new book is created with an eye to giving the reader a solid, practical, and clinically focused understanding of this important class of drugs, from basic science to a clear-headed discussion of complex topics such as combination therapies, drug-to-drug interactions, and resistance to antiplatelet agents. This important new book: * Begins with a concise but thorough discussion of platelet biology and pathophysiology so that readers understand how antiplatelet agents work and why they produce such a varied range of complications, from minor GI upset to potentially life-threatening conditions such as neutropenia, a critical shortage of white blood cells. * Thoroughly covers platelet function testing, including novel techniques. * Clarifies current best practice regarding the use of antiplatelet agents in both chronic and acute cardiovascular disease. * Reviews all types of antiplatelet agents from aspirin to recently approved drugs including indications, clinical outcomes, and side effects. Written by an international who s who of experts in the field, Antiplatelet Therapy in Cardiovascular Disease also includes an entire section covering the use of antiplatelet drugs in PCIs, including percutaneous valve repair, which makes this text particularly essential to interventional cardiologists.


List of Contributors, viii Foreword, xix Preface, xxi Section I: Platelet biology and pathophysiology 1 Platelet Pathophysiology and its Role in Thrombosis, 3 Paul A. Gurbel and Udaya S. Tantry 2 Platelet Receptors and Drug Targets: COX-1, 8 Thomas Hohlfeld and Karsten Schror 3 Platelet Receptors and Drug Targets: P2Y12, 14 Marco Cattaneo 4 Platelet Receptors and Drug Targets: GP IIb/IIIa, 21 Eliano Pio Navarese and Jacek Kubica 5 Platelet Receptors and Drug Targets: PAR1, Collagen, vWF, Thromboxane, and Other Novel Targets, 29 Ping Zhang, Lidija Covic, and Athan Kuliopulos 6 Role of Inflammation and Hypercoagulability in Thrombosis, 45 Paul A. Gurbel, Nachiket Apte, and Udaya S. Tantry Section II: Platelet function tests 7 Light Transmission Aggregometry, 53 Paul A. Gurbel, Martin Gesheff, Kevin P. Bliden, and Udaya S. Tantry 8 Vasodilator-Stimulated Phosphoprotein (VASP) Assay, 58 Marc Laine, Franck Paganelli, and Laurent Bonello 9 VerifyNow P2Y12 and Plateletworks Assays, 65 Matthew J. Price, Nicoline J. Breet, and Jurrien M. ten Berg 10 Multiplate Analyzer, 82 Martin Orban and Dirk Sibbing 11 Shear Stress-Based Platelet Function Tests, 92 Nicoline J. Breet and Jurrien M. ten Berg 12 Thrombelastography and Other Novel Techniques, 102 Udaya S. Tantry, Vijay A. Doraiswamy, Glenn Stokken, Marvin J. Slepian, and Paul A. Gurbel Section III: Antiplatelet pharmacology 13 Aspirin, 111 Karsten Schror and Thomas Hohlfeld 14 Cilostazol, 117 Seung-Whan Lee, Duk-Woo Park, and Seung-Jung Park 15 Abciximab, 125 J. Emilio Exaire and Jorge F. Saucedo 16 Tirofiban, 131 Marco Valgimigli, Arnoud W.J. van't Hof, and Christian Hamm 17 Eptifibatide, 142 Nevin C. Baker and Ron Waksman 18 Ticlopidine, 150 Fabiana Rollini, Francesco Franchi, Ana Muniz-Lozano, and Dominick J. Angiolillo 19 Clopidogrel, 160 Andrzej Budaj 20 Prasugrel, 166 Christoph Varenhorst, Anna Oskarsson, and Stefan James 21 Elinogrel, 173 Matthew J. Chung and Sunil V. Rao 22 Cangrelor, 180 Francesco Franchi, Fabiana Rollini, Ana Muniz-Lozano, and Dominick J. Angiolillo 23 Ticagrelor, 193 Anna Oskarsson, Christoph Varenhorst, and Stefan James 24 Thrombin Receptor Antagonists, 198 Flavio de Souza Brito and Pierluigi Tricoci Section IV: Percutaneous Coronary Intervention and Antiplatelet Therapy 25 Dual Antiplatelet Therapy Prior to Percutaneous Coronary Intervention, 209 Fabio Mangiacapra, Annunziata Nusca, Rosetta Melfi, and Germano di Sciascio 26 Duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation, 220 Joshua P. Loh and Ron Waksman 27 Antiplatelet Therapy for Patients with Acute Coronary Syndromes, 229 Michael A. Gaglia, Jr. and Ray V. Matthews 28 Antiplatelet Therapy in Stable Coronary Artery Disease, 237 Ana Laynez and Ron Waksman 29 Antiplatelet Therapy for Patients with Peripheral Arterial Disease, 245 Aung Myat, Yousif Ahmad, and Simon R. Redwood 30 Bleeding Risk and Outcomes of Patients Undergoing Percutaneous Coronary Intervention Treated with Antiplatelets, 253 Sa'ar Minha and Ron Waksman 31 Bleeding Definitions, 259 Sameer Bansilal, Deborah E. Aronson, and Roxana Mehran Section V: Antiplatelet Responsiveness 32 Personalizing Antiplatelet Therapy, 269 Paul A. Gurbel, Young-Hoon Jeong, and Udaya S. Tantry 33 Aspirin Resistance, 277 Muthiah Vaduganathan and Eli I. Lev 34 Clopidogrel Resistance, 285 Udaya S. Tantry, Kevin P. Bliden, Talha Meeran, and Paul A. Gurbel 35 Genetics of Clopidogrel Poor Response, 293 Pierre Fontana and Jean-Luc Reny 36 Proton Pump Inhibitors and Clopidogrel, 300 Michael A. Gaglia, Jr 37 Other Drug Interactions with Clopidogrel, 306 Eric R. Bates Index, 314

Product Details

  • ISBN13: 9781118275757
  • Format: Hardback
  • Number Of Pages: 348
  • ID: 9781118275757
  • weight: 704
  • ISBN10: 1118275756

Delivery Information

  • Saver Delivery: Yes
  • 1st Class Delivery: Yes
  • Courier Delivery: Yes
  • Store Delivery: Yes

Prices are for internet purchases only. Prices and availability in WHSmith Stores may vary significantly